Want to see GEHC full AI Analyst Report?
EBIT by Segment
Analyzes earnings before interest and taxes across different business segments, providing insight into which areas are most profitable and where there may be challenges or opportunities.Advanced Visualization has emerged as a higher run‑rate driver (post‑clearances and the Intelerad deal) while Imaging remains cyclical and sensitive to product cycles, tariffs and memory‑chip inflation that compressed margins; Patient Care Solutions is the clear laggard — installation timing and China weakness knocked EBIT down sharply — and represents the biggest near‑term downside risk. Pharmaceutical Diagnostics is the most stable, margin‑accretive engine supporting cash and backlog. Management expects H2 margin relief as price/cost actions and lower tariffs kick in.
Date | Other | Imaging | Advanced Visualization Solutions | Patient Care Solutions | Pharmaceutical Diagnostics | Advanced Imaging Solutions |
|---|---|---|---|---|---|---|
Jun 30, 2026 | $1.00M | $0.00 | $0.00 | -$26.00M | $250.00M | $525.00M |
Mar 31, 2026 | $5.00M | $180.00M | $299.00M | $10.00M | $197.00M | $0.00 |
Dec 31, 2025 | $2.00M | $264.00M | $376.00M | $74.00M | $234.00M | $0.00 |
Sep 30, 2025 | $2.00M | $240.00M | $271.00M | $27.00M | $220.00M | $0.00 |
Jun 30, 2025 | $1.00M | $188.00M | $267.00M | $60.00M | $213.00M | $0.00 |
Mar 31, 2025 | $2.00M | $199.00M | $261.00M | $48.00M | $205.00M | $0.00 |
Dec 31, 2024 | $1.00M | $149.00M | $526.00M | $106.00M | $212.00M | $0.00 |
Sep 30, 2024 | $1.00M | $287.00M | $232.00M | $82.00M | $193.00M | $0.00 |
Jun 30, 2024 | $1.00M | $286.00M | $178.00M | $78.00M | $200.00M | $0.00 |
Mar 31, 2024 | -$1.00M | $240.00M | $182.00M | $81.00M | $178.00M | $0.00 |